1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tong Ren Tang Technologies Co., Ltd. Class H

Tong Ren Tang Technologies Co., Ltd. Class H

0.40
USD
-0.10
(-19.35%)
920.32MMarket Cap
Mar 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.41
2.61
3.18
3.64
3.92
3.95
3.5
3.6
4.22
4.68
5.29
5.67
5.06
- -
Basic EPS, GAAP
0.32
0.36
0.42
0.47
0.52
0.53
0.33
0.37
0.4
0.46
0.46
0.41
0.31
- -
Free Cash Flow per Basic Share
0.15
0.04
0.1
-0.02
0.2
0.48
0.61
-0.26
0.68
0.44
0.35
-0.12
1.13
- -
Dividend per Share
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.16
0.16
0.16
0.16
0.18
0.18
- -
Book Value per Share
2.54
2.77
3.1
3.44
3.76
4.15
4.32
4.48
4.67
5.06
5.38
5.63
5.73
5.73
Tangible Book Value per Share
2.54
2.77
3.05
3.37
3.7
4.09
4.26
4.43
4.62
5.01
5.33
5.57
5.67
5.67
Basic Weighted Avg Shares
1,209
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
Sales/Revenue/Turnover
2,911
3,341
4,067
4,665
5,025
5,060
4,476
4,607
5,400
5,992
6,773
7,260
6,484
- -
Operating Margin (%)
21.13
21.3
21.68
21.59
23.21
23.66
20.96
20.96
19.9
20.03
16.73
13.57
12.37
- -
Depreciation Expense
47
61
75
79
85
88
160
270
250
262
277
290
334
- -
Net Income, GAAP
390
462
541
596
667
678
418
468
507
583
590
522
396
- -
Effective Tax Rate (%)
15.45
16.78
17.47
16.86
16.83
16.67
19.72
16.3
17.05
17.36
14.64
16.42
19.67
- -
Profit Margin (%)
13.4
13.83
13.3
12.77
13.27
13.4
9.33
10.15
9.39
9.73
8.71
7.19
6.11
- -
Working Capital
3,291
3,415
3,912
5,172
5,442
5,899
5,891
4,999
5,672
7,021
7,820
7,992
8,411
8,411
LT Debt
39
- -
- -
918
915
911
1,283
578
819
1,296
1,476
1,283
1,545
1,545
Total Equity
4,009
4,436
5,163
5,885
6,460
7,277
7,415
7,752
8,158
9,017
9,652
10,165
10,265
10,265
Return on Invested Capital (%)
15.63
13.53
14.64
13.45
13.22
12.35
8.45
8.54
9.24
9.67
8.59
6.85
5.14
- -
Return on Capital (%)
8.71
7.12
6.92
5.66
5.23
4.54
1.47
2.09
2.07
2.04
2.1
1.76
1.44
- -
Return on Common Equity (%)
15.02
13.58
14.39
14.23
14.46
13.38
7.7
8.31
8.66
9.35
8.83
7.4
5.45
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1,142
480
460
LT Borrowings
1,202
1,842
1,453
LT Finance Leases
81
93
91
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,281
1,281
1,281
Market Capitalization
- -
5,750
6,435

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
10,833
10,996
10,192
Cash, Cash Equivalents & STI
4,381
5,147
4,834
Accounts Receivable, Net
888
1,061
670
Inventories
5,166
4,631
4,547
Total Current Liabilities
2,841
2,282
1,781
Payables & Accruals
- -
- -
- -
ST Debt
1,142
480
460
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.19%
5.82%
0.98%
Free Cash Flow
-273.07%
-312.62%
-1,011.73%
Net Income, GAAP
-1.37%
-2.2%
-24.06%
Sales/Revenue/Turnover
5.22%
7.54%
-10.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
6,773
2024
- -
- -
7,260
2025
- -
- -
6,484

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.46
2024
- -
- -
0.41
2025
- -
- -
0.31

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.16
2024
- -
- -
0.18
2025
- -
- -
0.18

Company Description

Company Profile APIChatGPT
CEO
Chun You Zhang
Full Time Employees
3,951
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 20 Nansanhuan Zhonglu Road Beijing BE China 100079
IPO Date
Oct 31, 2000
Website
tongrentangkj.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tong Ren Tang Technologies Co. Ltd. (1666.HK) manufactures and sells traditional Chinese medicine products in Mainland China and Hong Kong. The company, founded in 1669 and headquartered in Beijing, operates through segments including the Company, Tong Ren Tang Chinese Medicine, and Others; it develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and produces ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, cosmetics, granules, pills, decoction pieces, Chinese herbal remedies, health supplements, and topical medicines. It also provides medical research and development, advertisement, Chinese medical consultations and treatments, internal and external surgery, medical examinations, traditional Chinese medicine department and hospital management activities, biochemical product processing, plant extraction and processing, and medical services. In addition, the company engages in technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products. Recent developments include entering into a supplemental trademark framework agreement with Tong Ren Tang Holdings on November 28, 2025, revising the scope of subsidiaries subject to licence fees and annual caps under the current trademark licence agreement for the years ending 2026 and 2027; renewing its Land Use Right Leasing Agreement with Tong Ren Tang Holdings; and in January 2024, entering an equity transfer agreement with Beijing Tong Ren Tang Healthcare Investment Co., Ltd. The company employs approximately 3,991 people and focuses on the healthcare sector, particularly drug manufacturing-general, with a subsidiary relationship to Beijing Tong Ren Tang Chinese Medicine (Hong Kong) Group Co. Ltd.